Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $5.31 USD
Change Today +0.59 / 12.50%
Volume 39.0K
TRIV On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 5:20 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

trivascular technologies inc (TRIV) Snapshot

Open
$4.68
Previous Close
$4.72
Day High
$5.50
Day Low
$4.68
52 Week High
10/17/14 - $16.62
52 Week Low
08/25/15 - $3.98
Market Cap
109.0M
Average Volume 10 Days
23.8K
EPS TTM
$-2.91
Shares Outstanding
20.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TRIVASCULAR TECHNOLOGIES INC (TRIV)

Related News

No related news articles were found.

trivascular technologies inc (TRIV) Related Businessweek News

No Related Businessweek News Found

trivascular technologies inc (TRIV) Details

TriVascular Technologies, Inc., a medical device company, develops and commercializes technologies to advance minimally invasive treatment of abdominal aortic aneurysms (AAA). The company offers Ovation System, a stent graft platform for the treatment of AAA through minimally invasive endovascular aortic repair. Its ovation system components include arotic body, iliac limbs, and fill polymer. The company markets and sells its products through direct sales organizations in the United States, Germany, the United Kingdom, the Netherlands, and Canada, as well as through distributors or agents in other markets. TriVascular Technologies, Inc. was incorporated in 2007 and is headquartered in Santa Rosa, California.

307 Employees
Last Reported Date: 03/9/15
Founded in 2007

trivascular technologies inc (TRIV) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $450.0K
Co-Founder and Chief Technology Officer
Total Annual Compensation: $296.3K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $356.2K
Compensation as of Fiscal Year 2014.

trivascular technologies inc (TRIV) Key Developments

TriVascular Technologies Announces First Patient Enrolled in the LUCY Study

TriVascular Technologies, Inc. announced the first patient enrolled and treated in the LUCY Study (TriVascular Evaluation of FemaLes who are Underrepresented Candidates for Abdominal Aortic AneurYsm Repair). The LUCY study is a prospective, consecutively enrolling, non-randomized multi-center post-market registry designed to evaluate the ultra-low profile (14F) Ovation platform when used in the endovascular treatment of abdominal aortic aneurysms (AAA) in female as compared to male patients. The lack of adequate treatment options, principally due to suboptimal, large bore, conventional EVAR systems, is a persistent issue for female AAA patients. Clinical literature shows that women diagnosed with AAA experience aortic expansion at a rate that is 40-80% faster than men, which can result in aortic rupture at smaller diameters. On average, women with abdominal aortic aneurysms have challenging access vessel anatomy and, often, hostile aortic neck anatomy. This fact, when combined with the technical limitations of conventional stent graft systems, results in significantly decreased access to on-label EVAR treatment for most women. The primary objective of the LUCY Study is to demonstrate the clinical outcomes and benefits associated with using the Ovation Abdominal Stent Graft platform in both female and male patients, including low access-related vascular complications, low mortality rates, and high eligibility rates even in patients who tend to have small access vessel diameters and challenging aortic neck anatomy. The study will enroll up to 225 subjects (75 females in the Treatment Group and 150 males in the Control Group) in up to 45 sites in the United States. Study results will provide a comparison of female and male patient outcomes. The primary endpoint is the Major Adverse Event (MAE) rate within 30 days of the initial procedure.

TriVascular Technologies, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Year 2015

TriVascular Technologies, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenue of $9,733,000 against $7,798,000 a year ago. Loss from operations was $12,813,000 against $12,739,000 a year ago. Loss before income tax expense was $14,791,000 against $14,495,000 a year ago. Net loss was $14,856,000 against $14,572,000 a year ago. Net loss per share, basic and diluted was $0.73 against $0.87 a year ago. Pro forma net loss was $14,856,000 against $15,275,000 a year ago. Pro forma net loss per share, basic and diluted was $0.73 against $0.82 a year ago. LBITDA was $12,758,000 against $11,909,000 a year ago. Adjusted LBITDA was $11,500,000 against $11,939,000 a year ago. The increase revenue was primarily attributable to the growth of the U.S. business as the U.S. field sales organization gained traction and customer utilization increased. The increase in operating expenses was driven primarily by an increase in selling, marketing and general and administrative expenses. For the six months, the company reported revenue of $17,758,000 against $14,832,000 a year ago. Loss from operations was $26,360,000 against $25,368,000 a year ago. Loss before income tax expense was $30,361,000 against $28,895,000 a year ago. Net loss was $30,493,000 against $28,995,000 a year ago. Net loss per share, basic and diluted was $1.50 against $3.30 a year ago. Pro forma net loss was $30,493,000 against $29,628,000 a year ago. Pro forma net loss per share, basic and diluted was $1.50 against $1.91 a year ago. LBITDA was $26,332,000 against $24,479,000 a year ago. Adjusted LBITDA was $24,027,000 against $23,977,000 a year ago. The company maintained its previously issued financial guidance which anticipates revenue for full-year 2015 to be in the range of $36 million to $39 million, reflecting year-over-year growth of approximately 13% to 23% over 2014 on a reported basis and 17% to 27% on a constant currency basis. Gross margin is expected to be between 60% and 62%.

TriVascular Technologies, Inc. and CRG Modify Term Loan Agreement

TriVascular Technologies, Inc. and Capital Royalty Partners II L.P. and its affiliate funds announced that they have amended the existing term loan agreement under which TriVascular previously borrowed $50 million. The transaction primarily amends the terms of the existing term loan agreement with CRG to increase the borrowing amount up to $95.0 million, net of financing fees. The company continues to have the option to access up to $15.0 million on or before December 31, 2015, subject to achievement of certain revenue milestones. The newly available borrowings of $30.0 million are dividend amongst two tranches. The first new tranche, consisting of $10.0 million in convertible notes with an interest rate of 8% and convertible into the company's common stock at a price of $8.00 per share, is scheduled to be funded at the closing on August 18, 2015, subject to customary closing conditions. The second new tranche consists of $20.0 million of borrowings that may be available to draw, upon achievement of certain revenue milestones, with the same interest, payment and other material terms as the existing borrowings under the loan. In connection with the transaction, the company plans to seek an amendment of its loan agreement with Century Medical, Inc. primarily to obtain consent to subordination of the additional borrowings.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TRIV:US $5.31 USD +0.59

TRIV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $16.74 USD -0.33
CR Bard Inc $193.79 USD -3.68
Endologix Inc $12.98 USD -0.06
Lombard Medical Inc $4.05 USD +0.29
St Jude Medical Inc $70.81 USD -1.81
View Industry Companies
 

Industry Analysis

TRIV

Industry Average

Valuation TRIV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.8x
Price/Book 7.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TRIVASCULAR TECHNOLOGIES INC, please visit www.trivascular.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.